Winter Storm Update – MSK is fully operational. Read more

A Phase II Study of Nivolumab plus Ipilimumab Immunotherapy for Patients with Recurrent or Metastatic Salivary Gland Cancer

Full Title

A Phase II Study of Nivolumab plus Ipilimumab in Patients with Recurrent/Metastatic Salivary Cancers


The purpose of this study is to evaluate the safety and effectiveness of the immunotherapy drugs nivolumab and ipilimumab for treating patients with recurrent or metastatic salivary gland cancer. Both drugs are approved for use together to treat melanoma; their use in this study is considered investigational.

Nivolumab and ipilimumab boost the power of the immune system to recognize and kill cancer cells. Nivolumab does this by targeting a protein called PD-1, while ipilimumab inhibits a protein called CTLA-4. Both drugs are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or metastatic salivary gland cancer that cannot be successfully treated with existing therapies.
  • At least 2 weeks must pass since the completion of prior chemotherapy and 4 weeks since previous radiation therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alan Ho at 646-888-4235.